US2011195905A1PendingUtilityA1

Apls for treating arthritis

36
Assignee: ARGENTIS PHARMACEUTICALS LLCPriority: Oct 28, 2009Filed: Oct 28, 2010Published: Aug 11, 2011
Est. expiryOct 28, 2029(~3.2 yrs left)· nominal 20-yr term from priority
Inventors:Arnold R. PostlewaiteAndrew H. KangLinda K. Myers
A61P 19/02A61K 38/16A61K 38/1709
36
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

One embodiment of a therapeutic composition comprises one or more APLs, e.g., APL A12, for treating diseases or disorders related to arthritis, including rheumatoid arthritis. Another embodiment includes a method of inducing a Th2-type cytokine secretion profile in a mammal, including administering a therapeutic amount of A12 analog peptide. Another embodiment includes a method for generating functional T regulatory cells, the method including administering a therapeutic amount of APL A12 to a RA patient.

Claims

exact text as granted — not AI-modified
1 . A therapeutic composition comprising an altered peptide ligand (APL) for treatment or inhibition of Rheumatoid Arthritis (RA) in patients in need thereof. 
     
     
         2 . The therapeutic composition of  claim 1 , wherein the APL comprises the amino acid sequence LGPKGQTGEBGIAGAKGDQGPKGEBGPA (SEQ ID NO: 2). 
     
     
         3 . The therapeutic composition of  claim 1  in injectable form. 
     
     
         4 . The therapeutic composition of  claim 1  in oral form. 
     
     
         5 . The therapeutic composition of  claim 1  in a dose range effective to treat or inhibit RA in patients in need thereof. 
     
     
         6 . The therapeutic composition of  claim 5  wherein the dose range is from about 30 μg/day to about 1,000 μg/day. 
     
     
         7 . The therapeutic composition of  claim 6  wherein the dose is about 30 μg/day. 
     
     
         8 . The therapeutic composition of  claim 6  wherein the dose is about 300 μg/day. 
     
     
         9 . The therapeutic composition of  claim 6  wherein the dose is about 1000 μg/day. 
     
     
         10 . The therapeutic composition of  claim 1 , further comprising one or more compounds selected from carriers, solvents, excipients, protecting groups, other biologically active compounds, and prodrugs. 
     
     
         11 . A method of treating or inhibiting RA comprising administering the therapeutic composition of  claim 1 . 
     
     
         12 . The method of  claim 11  wherein administering is to be performed over a period of time. 
     
     
         13 . The method of  claim 12  wherein administering comprises one or more administrations within one day. 
     
     
         14 . The method of  claim 12  wherein administering comprises one or more administrations over a period of time including one or more days. 
     
     
         15 . The method of  claim 11 , further comprising enhancing the potency of the therapeutic composition of  claim 1  using carbohydrates. 
     
     
         16 . A method of making the therapeutic composition of  claim 1 , including genetic or non-genetic procedures. 
     
     
         17 . A method of inducing a Th2-type cytokine secretion profile in a mammal, comprising administering a therapeutic amount of A12 analog peptide. 
     
     
         18 . A method generating functional T regulatory cells, the method comprising administering a therapeutic amount of APL A12 to a RA patient.

Join the waitlist — get patent alerts

Track US2011195905A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.